- Conditions
- Solid Tumors, ER+ Breast Cancer, Triple Negative Breast Cancer, TNBC, ARID1A Gene Mutation, Small Cell Lung Cancer, SCLC
- Interventions
- JAB-2485 (Aurora A inhibitor)
- Drug
- Lead sponsor
- Jacobio Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Detroit, Michigan • St Louis, Missouri • Dallas, Texas + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 16,095
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Venous Leg Ulcer
- Interventions
- Granexin
- Drug
- Lead sponsor
- Xequel Bio, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 3
- States / cities
- Augusta, Georgia • Spartanburg, South Carolina • Salem, Virginia
- Conditions
- Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
- Interventions
- Neratinib Oral Tablet, Ruxolitinib Oral Tablet
- Drug
- Lead sponsor
- Baylor Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Breast Cancer, Sarcoma, Bladder Cancer, Lung Cancer, Prostate Cancer, Cervical Cancers, Head and Neck Cancers, Adrenal Gland Tumors
- Interventions
- IDOV-Immune (oncolytic vaccinia virus)
- Biological
- Lead sponsor
- ViroMissile, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Houston, Texas • San Antonio, Texas
- Conditions
- Breast Cancer
- Interventions
- Focused Microwave Thermotherapy, Chemotherapy (control)
- Device · Drug
- Lead sponsor
- Medifocus, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Breast Cancer
- Interventions
- docetaxel, protein expression analysis, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy
- Drug · Genetic · Other + 1 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2011
- U.S. locations
- 2
- States / cities
- Nashville, Tennessee
- Conditions
- Early-stage Breast Cancer, Breast Carcinoma, DCIS
- Interventions
- Radiation: Accelerated Partial Breast Irradiation (APBI)
- Radiation
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 50 Years to 90 Years · Female only
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 10
- States / cities
- Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more
- Conditions
- Irritable Bowel Syndrome With Diarrhea
- Interventions
- Rezular 15mg, Placebo, Rezular
- Drug
- Lead sponsor
- AGI Therapeutics, Inc.
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 711 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Wilmington, North Carolina
- Conditions
- Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome
- Interventions
- Cyclophosphamide, filgrastim
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland
- Conditions
- Psoriasis
- Interventions
- Apremilast 30mg, calcipotriene and betamethasone dipropionate
- Drug
- Lead sponsor
- Derm Research, PLLC
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Actinic Keratosis
- Interventions
- Photodynamic therapy (PDT), Vitamin D3
- Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Breast Cancer, Healthy, no Evidence of Disease
- Interventions
- Random fine need aspiration (rFNA), Mammogram
- Procedure · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 35 Years to 60 Years · Female only
- Enrollment
- 385 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Fatigue, Physical Activity, Lupus Erythematosus, Systemic
- Interventions
- Experimental, Control
- Behavioral · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Chicago, Illinois
- Conditions
- Breast Cancer
- Interventions
- 99m Tc-TM
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Extensive Stage Small Cell Lung Cancer (ES-SCLC), NSCLC
- Interventions
- IDE-161, Pembrolizumab
- Drug
- Lead sponsor
- IDEAYA Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more
- Conditions
- Peanut Allergy
- Interventions
- Peanut in diet
- Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 4 Months to 11 Months
- Enrollment
- 333 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2023
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Chronic Primary Immune Thrombocytopenia (ITP)
- Interventions
- Kedrion IVIG 10%
- Biological
- Lead sponsor
- Kedrion S.p.A.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Shirley, New York • Greenville, North Carolina
- Conditions
- Tinea Pedis
- Interventions
- 33525, Placebo
- Drug
- Lead sponsor
- Medicis Global Service Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 322 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 10
- States / cities
- Miami, Florida • Miramar, Florida • Augusta, Georgia + 7 more
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- fluzone, pneumovax
- Biological
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 65 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Skin Neoplasms
- Interventions
- Patient activation and education (PAE), PAE plus physician activation (PAE + MD), PAE physician activation, plus teledermoscopy (PAE +MD +TD)
- Behavioral
- Lead sponsor
- Harvard School of Public Health (HSPH)
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 726 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Multiple Myeloma, Amyloidosis, Cryoglobulinemia, Castleman's Disease, Light Chain Deposition Disease, Heavy Chain Deposition Disease, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma, Plasma Cell Leukemia
- Interventions
- Not listed
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Timeline
- 2018 – 2029
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Ichthyosis
- Interventions
- TMB-001, Matching Vehicle
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 153 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more
- Conditions
- Acne Vulgaris
- Interventions
- Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
- Drug · Other
- Lead sponsor
- Dermira, Inc.
- Industry
- Eligibility
- 9 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 38
- States / cities
- Phoenix, Arizona • Anaheim, California • Los Angeles, California + 30 more
- Conditions
- Androgenetic Alopecia
- Interventions
- TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
- Device
- Lead sponsor
- Apira Science, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 88 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 4
- States / cities
- Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more